Impact of a pharmacist adherence intervention on medication beliefs and drug-related problems in coronary patients - a process evaluation of the MIMeRiC trial
Abstract
Background: The Motivational Interviewing and Medication Review in Coronary Heart Disease (MIMeRiC) randomized controlled trial investigated the effects of a pharmacist-led intervention at a cardiology clinic on patient adherence and clinical outcomes. The results demonstrated that the intervention group had increased adherence to cholesterol-lowering medications and aspirin, as well as improved overall beliefs about medicines. However, the intervention did not lead to a higher proportion of patients reaching the target for low-density lipoprotein cholesterol (LDL-C) levels. This paper reports on the implementation of the intervention and explores potential mechanisms underlying these outcomes, focusing on the content of medication reviews, quality of prescribing, and changes in beliefs about medicines.
Methods: Medication reviews were evaluated by classification of identified drug-related problems (DRPs), actions taken to address these problems, and the outcomes of those actions, utilizing data from electronic health records (EHR). The Medication Assessment Tool for secondary prevention of Coronary Heart Disease (MAT-CHDsp) was applied to EHR data to evaluate prescribing quality. Beliefs about medicines were evaluated using the Beliefs about Medicines Questionnaire specific (BMQ-S), completed by participants at baseline and follow-up. Descriptive and comparative statistics were used to analyze the data.
Results: Medication reviews were conducted for 144 of the 159 patients…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 159 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.